Velpatasvir
- Generic Name
- Velpatasvir
- Brand Names
- Epclusa, Vosevi
- Drug Type
- Small Molecule
- Chemical Formula
- C49H54N8O8
- CAS Number
- 1377049-84-7
- Unique Ingredient Identifier
- KCU0C7RS7Z
- Background
Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Velpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with Ribavirin.
...
- Associated Conditions
- Chronic Hepatitis C - Genotype 3, Chronic Hepatitis C Genotype 1, Chronic hepatitis C genotype 2, Chronic hepatitis C genotype 5, Genotype 4 Chronic Hepatitis C, Genotype 6 chronic hepatitis C infection
- Associated Therapies
- -
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05717400
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT03513393
- Locations
- 🇳🇱
Radboud university medical Center, Nijmegen, Gelderland, Netherlands
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Valme University Hospital
- Target Recruit Count
- 1128
- Registration Number
- NCT02333292
- Locations
- 🇪🇸
Valme University Hospital, Seville, Andalusia, Spain
Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 19
- Registration Number
- NCT02002767
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 103
- Registration Number
- NCT01740791
- Locations
- 🇺🇸
West Coast Clinical Trials, LLC, Costa Mesa, California, United States
🇺🇸Avail Clinical Research, LLC, DeLand, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.